Search clinical trials for: Dipeptidyl Peptidase-4 Inhibitor (DPP-4)

Total 2585 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Recurrent Acute Biphenotypic Leukemia | Blasts 20 Percent or More of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk...

United States
Hadassah Medical Organization

Completed

T Cell Vaccination in Patients With Progressive Multiple Sclerosis

Multiple Sclerosis

Israel
Sanofi
Kowa Company, Ltd.

Completed

TOFO Insulin Combination Trial

Type 2 Diabetes Mellitus

Japan
Chiang Mai University

Completed

Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor

Diabetes Mellitus, Type 2 | Ischemic Heart Disease

Thailand
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Nanjing First Hospital, Nanjing Medical University; Wuxi People's Hospital; Changzhou... and other collaborators

Recruiting

Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function in T2DM Patients With Mild Cognitive Impairment: a Multicenter, Randomized, Parallel Controlled Clinical Trial (LIGHT-MCI)

Type 2 Diabetes Mellitus | Mild Cognitive Impairment

China
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
Sherief Abd-Elsalam

Recruiting

Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM

dm

Egypt
Clinision

Withdrawn

Evaluating the Glycemic Control wIth Vildagliptin and Metformin Combination Therapy. (GRIP)

Diabetes Mellitus, Type 2
Lund University

Completed

Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 Diabetes

Diabetes

Sweden
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Ganzhou Hemay Pharmaceutical Co., Ltd

Recruiting

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment

Psoriasis

China
Tetra Discovery Partners

Recruiting

A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome

Fragile X Syndrome

United States
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Solid Tumors

United States, China, Belgium, Australia, Italy, Korea, Republic of, Germany, Netherlands, Poland, Romania, Thailand
Tetra Discovery Partners

Recruiting

A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome

Fragile X Syndrome

United States
Amgen

Completed

A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole

Healthy Volunteers

United States
Tianjin Hemay Bio-Tech Co., Ltd

Unknown

Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects

Psoriasis

China
Novartis Pharmaceuticals

Completed

Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin

Type-2 Diabetes Mellitus

Hong Kong
Centro de Diabetes Curitiba Ltda

Completed

Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability (BoneGlyc)

Type 2 Diabetes Mellitus | Menopause | Osteoporosis | Osteopenia

Brazil
Novartis Pharmaceuticals

Completed

Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin (ADDONIS)

Type 2 Diabetes Mellitus (T2DM)

France
Novartis

Completed

A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Japan
Novartis Pharmaceuticals

Completed

VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Spain, Poland, South Africa, Taiwan, Hong Kong, Norway, Italy, Bulgaria, Latvia, Lithuania, Germany, Turkey, Argentina, Israel, Korea, Republic of, Dominican Republic, Guatemala, Brazil, Colombia, Peru, Philippines, Russian Federation and more
University of Dundee

Completed

DPP4inhibitors in Type 1 Diabetes

Type 1 Diabetes | Hypoglycaemia

United Kingdom
Profil Institut für Stoffwechselforschung GmbH

Completed

Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment

Diabetes Mellitus

Germany
Novartis

Completed

Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%

Diabetes Mellitus, Type 2

Switzerland
AstraZeneca

Completed

Drug Interaction Study - Assess Pharmacokinetics of Both AZD5672 and Atorvastatin

Healthy Volunteers | Pharmacokinetics

United Kingdom
AstraZeneca
Quintiles, Inc.

Completed

A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart

Rheumatoid Arthritis

United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...
Safeway Foundation

Recruiting

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

Breast Cancer

United States
Ohio State University Comprehensive Cancer Center
Bristol-Myers Squibb

Completed

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

Lung Metastases | Liver Metastases | Recurrent Melanoma | Stage IV Melanoma | Tumors Metastatic to Brain

United States
National Cancer Institute (NCI)

Completed

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma and other conditions

United States
Bayer

Completed

Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)

Hypertension, Pulmonary

Japan
Genzyme, a Sanofi Company

Completed

Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies (EXOSKEL)

Gaucher Disease

Canada, Russian Federation, Tunisia
Stanford University
National Cancer Institute (NCI)

Terminated

Ipilimumab and Local Radiation for Selected Solid Tumors

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
OHSU Knight Cancer Institute
Bristol-Myers Squibb; Oregon Health and Science University

Completed

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Astex Pharmaceuticals, Inc.

Completed

Effect of Food on Blood Levels of ASTX727

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Hoffmann-La Roche

Completed

An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

Neoplasms

France, Hungary, Spain, Korea, Republic of, United Kingdom, United States, Croatia, Greece, Portugal, Germany, Bosnia and Herzegovina, Belgium, South Africa, Israel, Romania, New Zealand, Italy, Canada, Netherlands, Egypt, Russian... and more
The First Affiliated Hospital of Xiamen University

Unknown

Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes

T2DM

China
Shanghai Jiao Tong University School of Medicine

Unknown

Metabolomic Variations in the Saxagliptin-Treated Type 2 Diabetes Mellitus Patients

Type 2 Diabetes

China
AstraZeneca

Completed

Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France (DIAPAZON)

Type 2 Diabetes Mellitus (T2D)
Sheba Medical Center

Completed

Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease (VAAST)

Type 2 Diabetes Mellitus | Ischemic Heart Disease

Israel
Ananda Basu, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); DexCom... and other collaborators

Completed

SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus (CiQ-SGLT2)

Type 1 Diabetes

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Poorly Differentiated Thyroid Gland Carcinoma | Recurrent Differentiated Thyroid Gland Carcinoma | Columnar Cell Variant Thyroid Gland Papillary Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Metastatic Thyroid Gland Follicular Carcinoma | Metastatic Thyroid Gland Papillary... and other conditions

United States
Monash University
Universiti Kebangsaan Malaysia Medical Centre

Terminated

Linagliptin in Schizophrenia Patients

Schizophrenia

Malaysia
Boehringer Ingelheim

Terminated

Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Philippines
Syntrix Biosystems, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis

Psoriasis

United States
PegBio Co., Ltd.

Recruiting

Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)

China, Taiwan, Hong Kong
Takeda

Completed

An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus (TRACK)

Type 2 Diabetes Mellitus

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Diabetes Mellitus, Type 2

United States, Spain, Taiwan, United Kingdom, Czechia, Bulgaria, Israel, Canada, Germany, Malaysia, Argentina, Hungary, Russian Federation, Poland, Ukraine, Korea, Republic of, Croatia, Japan, Netherlands, Portugal, South Africa, ... and more
Handok Inc.

Completed

Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients (TELIUS)

Type2 Diabetes Mellitus

Korea, Republic of
Sanofi

Completed

Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin

Type 2 Diabetes Mellitus

Russian Federation

Search clinical trials for: Dipeptidyl Peptidase-4 Inhibitor (DPP-4)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations